VTAK Announces Definitive Merger Agreement to Acquire 100% of Fly Flyte Inc.
Rhea-AI Summary
VTAK (NYSE American: VTAK) completed acquisition of the remaining 80.02% equity interest in Fly Flyte, making Flyte a wholly owned subsidiary and consolidating a revenue-generating, asset-backed regional aviation platform.
Flyte operates under FAA 14 CFR Part 135 using certified Cirrus Vision Jets, providing immediate cash flow, tangible aircraft and infrastructure, and consolidated revenues going forward.
Positive
- Conversion of Flyte to 100% ownership, enabling full consolidation of revenues and assets
- Flyte operates under FAA 14 CFR Part 135 with certified Cirrus Vision Jets
- Immediate cash flow from a revenue-generating aviation operator adds operating leverage
- Asset-backed platform with tangible aircraft, infrastructure, and trained flight crews
Negative
- Transaction remains subject to customary closing conditions, including shareholder approval, creating execution uncertainty
News Market Reaction – VTAK
On the day this news was published, VTAK gained 25.55%, reflecting a significant positive market reaction. Argus tracked a peak move of +65.1% during that session. Argus tracked a trough of -12.4% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $642K to the company's valuation, bringing the market cap to $3.16M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VTAK was down 2.84% while peer NUWE appeared in momentum scanners up 5.43%. Other peers show mixed moves, indicating this aviation acquisition is being priced as company-specific rather than sector-driven.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Heart failure asset deal | Positive | -1.2% | Completion of acquisition of CPNS System heart failure assets via subsidiary. |
| Apr 23 | Heart failure asset agreement | Positive | +4.6% | Definitive agreement to acquire CPNS System assets via Cardionomix. |
| Feb 04 | PeriKard acquisition closing | Positive | -2.6% | Closing of all-stock acquisition of PeriKard ventricular-focused technology. |
| Jan 15 | PeriKard acquisition agreement | Positive | -5.7% | Definitive all-stock agreement to acquire 100% of PeriKard interests. |
Acquisition announcements have often seen muted or negative next-day moves, with 3 of 4 past deals followed by declines.
Across prior acquisition announcements on Jan 15, 2025, Feb 4, 2025, Apr 23, 2025, and May 6, 2025, VTAK used M&A to add heart failure and pericardial-access technologies through all-stock and asset transactions. Price reactions were mixed to negative, with only the Apr 23, 2025 Cardionomic agreement producing a gain. Today’s move to 100% ownership of Fly Flyte extends that acquisition-driven strategy into asset-backed aviation operations.
Historical Comparison
In prior acquisition announcements, VTAK’s average next-day move was -1.22%, suggesting that the market has historically reacted cautiously to its deal-making, a context for this Flyte transaction.
VTAK’s deal history shows expansion from cardiac assets (CPNS System, PeriKard) into broader therapeutic tools, and now into aviation via Fly Flyte. The pattern reflects use of acquisitions to add operating platforms and technologies rather than relying solely on internal development.
Market Pulse Summary
The stock surged +25.6% in the session following this news. A strong positive reaction aligns with VTAK’s shift from minority investor to full owner of a revenue-generating aviation operator. Prior acquisitions produced mixed post-news moves, with an average -1.22% next-day change, so sustained strength could depend on how quickly consolidated Flyte revenues and cash flow appear in filings and how investors assess dilution and execution risks from the broader financing structure around the deal.
Key Terms
faa 14 cfr part 135 regulatory
whole-aircraft parachute technical
autonomous landing technical
form 8-k regulatory
evtol technical
AI-generated analysis. Not financial advice.
Transaction Delivers Wholly Owned, Scalable Asset-Backed, Aviation Platform with Accelerating Revenue and Consolidated Control
Positions VTAK at the Center of High-Growth Regional Air Mobility Ahead of Industry-Wide eVTOL Commercialization
FORT MILL, S.C., March 10, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) today announced that it has completed the acquisition of the remaining
The transaction converts Flyte from a minority strategic investment into a wholly owned operating subsidiary, establishing VTAK as the owner of a revenue-generating, asset-backed aviation platform with certified aircraft, tangible infrastructure, and scalable fleet economics.
Full Ownership, Consolidated Revenue, Immediate Cash Flow
Flyte operates under FAA 14 CFR Part 135 certification, deploying Cirrus Vision Jets across high-frequency, short-haul regional routes where commercial airline capacity remains constrained or does not exist. The business currently generates revenue through the operation of aircraft equipped with advanced integrated safety systems, including whole-aircraft parachute technology and Safe Return™ autonomous landing capability.
With full ownership now complete, all Flyte operations, assets, and economics are fully consolidated within VTAK, providing direct exposure to operating performance and long-term equity value creation. Going forward, Flyte’s financial results will be consolidated into VTAK’s financial statements.
Strategic Impact for VTAK Shareholders
With full ownership of Flyte, VTAK:
• Completes a transformative business combination
• Expands into asset-backed transportation infrastructure
• Aligns capital, governance, and growth strategy under a single structure
• Positions shareholders for long-term equity upside through disciplined fleet expansion
The acquisition reflects VTAK’s strategy of selectively deploying capital into operating businesses with tangible assets, scalable infrastructure, and clear paths to durable value creation.
Inflection Point and Valuation Transformation
“This transaction marks a defining inflection point for VTAK,” said David Jenkins, CEO and Chairman of VTAK. “We have transformed from a minority investor into the owner of an operating aviation business with tangible assets, certified infrastructure, and immediate revenue. Management believes full ownership of Flyte materially enhances VTAK’s long-term valuation profile by contributing consolidated revenues, asset backing, and the potential for substantial operating leverage.”
Asset-Backed Growth Platform Built for Disciplined Scale
Unlike pre-commercial or speculative aviation concepts, Flyte operates today with:
• Certified aircraft and trained flight crews
• Established regulatory approvals and operating infrastructure
• Active customer demand across multiple premium, high-volume, regional markets
The Flyte model emphasizes capital efficiency, high aircraft utilization, and measured expansion aligned with demand and infrastructure readiness, supporting sustainable growth and long-term value creation rather than speculative deployment.
Positioned for Regional Air Mobility - Operating Today, Optionality Tomorrow
Flyte operates in many of the same short-haul corridors targeted by future advanced air mobility and electric aircraft developers. By operating today with certified aircraft and established infrastructure, Flyte generates real operating data, route density, and customer engagement, while maintaining flexibility to participate in future industry evolution.
This structure allows VTAK to participate in long-term regional air mobility growth without reliance on extended certification timelines - pairing current revenue generation with future strategic optionality.
Flyte Leadership Perspective
“Being listed on a national stock exchange and becoming a wholly owned subsidiary of VTAK provides Flyte with aligned governance, capital support, and a clear execution framework,” said Marc Sellouk, CEO and Founder of Flyte. “Our focus remains disciplined execution - operating safely, scaling responsibly, and building a durable aviation operating platform designed for long-term value creation.”
Additional Information
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company’s Current Report on Form 8-K filed March 9, 2026, for additional details regarding the transaction, which is subject to customary closing conditions, including shareholder approval with respect to certain elements of the transaction.
About Flyte
Flyte is a technology-enabled Regional Air Mobility Company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter travel.
Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.
For more information, visit www.flyte.travel
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The company focuses on bringing new technologies to market through collaboration with physicians and continuous product innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “focus,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our belief that full ownership of Flyte materially enhances VTAK’s long-term valuation profile by contributing consolidated revenues, asset backing, and the potential for substantial operating leverage and our focus remaining on disciplined execution - operating safely, scaling responsibly, and building a durable aviation operating platform designed for long-term value creation. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. Unless otherwise required by law, the Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether because of new information, a future event, or otherwise and such statements are made only as of the date hereof. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Form 10-K and Form 10-Q’s, including but not limited to the discussion under “Risk Factors” therein, which the Company has filed with the SEC and which may be viewed at www.sec.gov.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
###
